articleEnhertu HER2-directed cancer treatment: key trials and results1 October 2021 | By Anna Begley (European Pharmaceutical Review)EPR's Anna Begley reviews some of the latest results for AstraZeneca’s Enhertu (trastuzumab deruxtecan) HER2-directed cancer therapy.
newsEnhertu improves survival in Phase III breast cancer trial10 August 2021 | By Anna Begley (European Pharmaceutical Review)Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine.
articleAntibody-drug conjugates: challenges, solutions and future potential20 April 2021 | By Dave Elder (David P Elder Constultancy), Stacey Treichler (Catalent)The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.
newsEnhertu® made available to breast cancer patients on UK’s Cancer Drugs Fund20 April 2021 | By Hannah Balfour (European Pharmaceutical Review)Enhertu® (trastuzumab deruxtecan) has been made available to allow for more safety and efficacy data to be collected prior to the NICE’s decision about its routine use on the NHS.
newsUK conditionally approves new treatment for HER2 positive breast cancer16 February 2021 | By Hannah Balfour (European Pharmaceutical Review)The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results.
newsEC approves Nilemdo™ (bempedoic acid) for lowering cholesterol9 April 2020 | By Victoria Rees (European Pharmaceutical Review)The European Commission has granted Esperion approval for Nilemdo, the company has sold commercialisation rights to Daiichi Sankyo.
news75 percent of nanopharmaceuticals are being developed for oncology8 April 2020 | By Hannah Balfour (European Pharmaceutical Review)A report states that three quarters of the roughly 230 nanopharmaceuticals in clinical development are for use as targeted cancer therapeutics.
articleFive of the most recent developments in anti-cancer therapeutics27 February 2020 | By Hannah Balfour (European Pharmaceutical Review)European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
newsTop five pharma companies saw overall decline in Q3 20198 January 2020 | By European Pharmaceutical ReviewResearch has found that the top five pharmaceutical companies averaged a Market Capitalisation decline of five percent in Q3 of 2019.
newsReport indicates seasonal influenza vaccine market in Asia will reach $1bn by 20283 January 2020 | By Hannah Balfour (European Pharmaceutical Review)A new report indicates that drug launches and new formulations will drive the growth of the seasonal influenza vaccine market in China, India and Japan from $914m in 2018 to $1.05bn in 2028.
newsFirst annual Pharmaceutical Invention Index released12 November 2019 | By Rachael Harper (European Pharmaceutical Review)The first Pharmaceutical Invention Index, which looks at the breadth and depth of novel agents currently being developed within the most innovative pharma pipelines, has been released.
newsHER2-positive metastatic breast cancer treatment granted Priority Review21 October 2019 | By Rachael Harper (European Pharmaceutical Review)Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
newsDaiichi Sankyo enrols first patient in Phase III acute myeloid leukaemia trial17 October 2016 | By Niamh Louise Marriott, Digital Content ProducerDaiichi Sankyo has enrolled their first patient in the global phase 3 QuANTUM-First study evaluating the oral FLT3-ITD inhibitor quizartinib in patients...
newsDaiichi Sankyo Phase 1 HER2-targeting antibody drug safe and effective to treat breast cancer11 October 2016 | By Niamh Louise Marriott, Digital Content ProducerDS-8201a is an investigational antibody drug conjugate comprised of a humanised anti-HER2 antibody attached by a peptide linker to a novel topoisomerase...
newsServier Canada to market edoxaban in Canada27 June 2016 | By Victoria White, Digital Content ProducerEdoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting...
